[Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
34 patients with disseminated malignant melanoma (stage III) were randomized to the following therapy groups: Chemotherapy (MeCCNU, NSC 99441; 200 mg/m2, given orally every 8 weeks), or immuno-chemotherapy (1 mg Corynebacterium parvum i.v., on days 1-4 + MeCCNU 200 mg/m2 on day 8, repeated every 7 weeks). Total therapy response rate was 33%; total and partial remissions were achieved in 26% of the patients receiving chemotherapy, and in 40% under immuno-chemotherapy. Interim life table analysis shows that in the group receiving C. parvum + MeCCNU 50% of the patients survived more than 12 months, whereas in the group with MeCCNU survival of 50% was 6 months. Pretreatment with C. parvum did not only potentiate the therapeutic effect, but also reduce the myelosuppression of MeCCNU.
D001428:Bacterial Vaccines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011379:Prognosis; D011425:Propionibacterium acnes / Q000276:immunology; D012075:Remission, Spontaneous; D012673:Semustine / Q000627:therapeutic use*
D001428:Bacterial Vaccines; D009607:Nitrosourea Compounds; D012673:Semustine
Immuno-Chemotherapie bei Patienten mit disseminiert metastasierendem Melanom Stadium III Randomisierte Studie mit Methyl-CCNU versus C. parvum plus Methyl-CCNU.